← Russell 3000 cross-section

LAB STANDARD BIOTOOLS INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$255m
Revenue TTM
$64m
Net income TTM
$85m
Free cash flow
$-83m
Composite score
40.2
Sector rank
#2761

Valuation

P / E
3.0
EV / EBITDA
EV / sales
-3.5
FCF yield
-32.32%
Earnings yield vs 10-yr
28.50pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
132.6%
EBITDA margin
-131.2%
ROE
15.7%
ROIC
-141.4%
Revenue growth
-58.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In addition, the Company is eligible to receive additional contingent earnout payments of up to $ 50.0 million based on the achievement of specified revenue thresholds for SomaScan assay services and related products during fiscal year 2026. The following tables summarize the financial results of the discontinued operations: 9 (1) During the six months ended June 30, 2026, the Company recognized revenue of $ 29.8 million related to the transaction price under the Collaboration Agreement with Illumina, which primarily reflects the release of the deferred revenue balance previously established under the Collaboration Agreement upon the sale of the SomaScan Business. …STANDARD BIOTOOLS INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →